Modelling the Risk of Visual Field Loss Arising from Long-Term Exposure to the Antiepileptic Drug Vigabatrin: A Cross-Sectional Approach

@article{Wild2013ModellingTR,
  title={Modelling the Risk of Visual Field Loss Arising from Long-Term Exposure to the Antiepileptic Drug Vigabatrin: A Cross-Sectional Approach},
  author={John M Wild and David Fone and Saleh Aljarudi and Charlotte Lawthom and Philip E. M. Smith and Robert Gordon Newcombe and Gareth D. Lewis},
  journal={CNS Drugs},
  year={2013},
  volume={27},
  pages={841-849}
}
BackgroundThe antiepileptic drug vigabatrin has been used widely since 1989, but has only been approved for use in the US since 2009. The risk:benefit of vigabatrin is generally predicated upon an assumed frequency of associated visual field loss (VAVFL) of approximately 31 %. This estimate is based upon relatively short-term usage (up to 4–5 years) and it is essential to determine whether the frequency of VAVFL increases with longer-term usage.ObjectiveThe aim of this study was to model, from… CONTINUE READING

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 47 REFERENCES

Clinical pharmacology of vigabatrin

PJ Schechter
  • Br J Clin Pharmacol. 1989;27(Suppl 1):S19–22
  • 1989
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Sensitivity and specificity of shortduration transient visual evoked potentials (SD-tVEP) in discriminating normal from glaucomatous eyes

C Pillae, R Ritch, P. Derr
  • Invest Ophthalmol Vis Sci
  • 2013

Three-year results from the Sabril Registry continue to yield low rate of visual field defects. Poster presented at the 66th Annual Meeting of the American Epilepsy

RC Sergott, R Foroozan, JM Pellock
  • 2012
VIEW 1 EXCERPT